It entered phase 1 over three years ago. If that tells us anything.
It's a fair point and one that came up during Q&A of the CC. The new CEO seems to be committed to more rapidly developing the drug. We should have some preliminary idea of what they have, if anything, after the Phase 1 is complete. PGNX hasn't given a firm timetable I don't believe of when they expect the Phase 1 to be complete though they did guide for another interim update in the next few weeks.
Market Data 
Markets 
AI
